A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
ClinicalTrials.gov ID
NCT01903720
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
71Actual
Last Update Posted
Apr 17, 2019Actual
Start Date
Jul 16, 2013Actual
Primary Completion Date
Sep 24, 2014Actual
Completion Date
Mar 30, 2015Actual
Brief Summary
This study will evaluate the safety and efficacy of OZURDEX® (700 µg dexamethasone implant) in patients with macular edema associated with branch retinal vein occlusion.
Macular Edema
Retinal Vein Occlusion
dexamethasone implant
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of macular edema
Best corrected visual acuity of approximately 20/400 to 20/40 in the study eye
Exclusion Criteria:
Use of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month
Intraocular surgery, including cataract surgery, and/or laser surgery of any type within 3 months